↓ Skip to main content

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model

Overview of attention for article published in Brazilian Journal of Medical and Biological Research, May 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
45 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
Published in
Brazilian Journal of Medical and Biological Research, May 2015
DOI 10.1590/1414-431x20143962
Pubmed ID
Authors

J.T. Stefano, I.V.A. Pereira, M.M. Torres, P.M. Bida, A.M.M. Coelho, M.P. Xerfan, B. Cogliati, D.F. Barbeiro, D.F.C. Mazo, M.S. Kubrusly, L.A.C. D'Albuquerque, H.P. Souza, F.J. Carrilho, C.P. Oliveira

Abstract

Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed to diethylnitrosamine for 6 weeks. The NASH group (n=10) received vehicle and the sorafenib group (n=10) received 2.5 mg·kg-1·day-1 by gavage. A control group (n=4) received only standard diet and vehicle. Following treatment, animals were sacrificed and liver tissue was collected for histologic examination, mRNA isolation, and analysis of mitochondrial function. Genes related to fibrosis (MMP9, TIMP1, TIMP2), oxidative stress (HSP60, HSP90, GST), and mitochondrial biogenesis (PGC1α) were evaluated by real-time quantitative polymerase chain reaction (RT-qPCR). Liver mitochondrial oxidation activity was measured by a polarographic method, and cytokines by enzyme-linked immunosorbent assay (ELISA). Sorafenib treatment restored mitochondrial function and reduced collagen deposition by nearly 63% compared to the NASH group. Sorafenib upregulated PGC1α and MMP9 and reduced TIMP1 and TIMP2 mRNA and IL-6 and IL-10 protein expression. There were no differences in HSP60, HSP90 and GST expression. Sorafenib modulated PGC1α expression, improved mitochondrial respiration and prevented collagen deposition. It may, therefore, be useful in the treatment of liver fibrosis in NASH.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Belgium 1 2%
Unknown 44 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 24%
Student > Bachelor 7 16%
Student > Master 6 13%
Student > Ph. D. Student 3 7%
Other 2 4%
Other 4 9%
Unknown 12 27%
Readers by discipline Count As %
Medicine and Dentistry 10 22%
Pharmacology, Toxicology and Pharmaceutical Science 4 9%
Biochemistry, Genetics and Molecular Biology 4 9%
Agricultural and Biological Sciences 4 9%
Arts and Humanities 2 4%
Other 6 13%
Unknown 15 33%